Directorate Change

RNS Number : 5926P

Alliance Pharma PLC

30 May 2018

 

For immediate release

30 May 2018

 

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

Directorate Change

Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, announces that Thomas Casdagli, a Non-Executive Director of the Company, has decided to step down from Alliance's Board after nine years. Mr Casdagli, a partner of MVM Life Science Partners LLP, will leave Alliance as of 30 May 2018.

David Cook, Alliance Pharma's Chairman, commented: "On behalf of the Board, I would like to thank Tom for his very significant contribution to Alliance over the past nine years. We wish him well for the future."

Thomas Casdagli added: "It has been a pleasure working with Alliance during my tenure on the Board. The Company has transformed over this period from a UK-focused established products business to a global pharmaceutical company with good organic and acquisitive growth prospects." 

For further information:

Alliance Pharma plc                                                                                 + 44 (0) 1249 466966

Peter Butterfield, Chief Executive Officer

Andrew Franklin, Chief Financial Officer

www.alliancepharma.co.uk 

Buchanan                                                                                                   + 44 (0) 20 7466 5000

Mark Court / Sophie Wills / Gemma Mostyn-Owen

Numis Securities Limited                                                                         + 44 (0) 20 7260 1000

Nominated Adviser: Michael Meade / Freddie Barnfield

Corporate Broking: James Black / Toby Adcock

Investec Bank plc                                                                                     [phone]

Corporate Finance: Daniel Adams / Ed Thomas

Corporate Broking: Patrick Robb / Rob Baker

Notes to editors:

About Alliance Pharma

Alliance, founded in 1998, is an international specialty pharmaceutical group based in Chippenham, Wiltshire, UK. The Group has sales in more than 100 countries worldwide via direct sales, joint ventures and a wide network of distributors.  Alliance has a strong track record of acquiring the rights to established niche products and it currently owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. The Group continues to explore opportunities to expand its product portfolio.

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.

 

END

 

 

BOAFMGZKVLRGRZM